@ unresectable or metastatic BTC patients with histologically proven adenocarcinoma of gallbladder or intrahepatic bile ducts , Eastern Cooperative Oncology Group ( ECOG ) @-@ were randomised to gemcitabine ( @ mg/m@ once weekly , first @-weeks +@ - week rest followed by once @-weeks +@ - week rest ) plus sorafenib ( @ mg twice daily ) or placebo .